Charles River director sells 33,561 shares at $300

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) director James C. Foster reported an option exercise-and-sale transaction in the company’s common stock. On August 25, 2026, he exercised stock options covering 33,561 shares of common stock at exercise prices of $194.12 and $208.44 per share, receiving the underlying shares.

On the same date, he sold 33,561 shares of common stock at $300.00 per share in an open market or private transaction. According to the filing, this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster also reports indirect holdings of common stock through several trusts and Grantor Retained Annuity Trusts.

Insider Trade Summary 10b5-1

Exercise and Sale: 33,561 shares ($3.38M approx. pre-tax spread)

Exercise and Sale 10 txns

Insider FOSTER JAMES C

Role Director

Sold 33,561 shs ($10.07M)

Approx. gross sale proceeds $10.07M

Approx. exercise cost $6.69M

Approx. pre-tax spread $3.38M

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	21,132	$0.00	$0.00
Exercise	Stock Options (Right to Buy)	12,429	$0.00	$0.00
Exercise	Common Stock	21,132	$194.12	$4.10M
Exercise	Common Stock	12,429	$208.44	$2.59M
Sale	Common Stock F1	33,561	$300.00	$10.07M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 19,473 contracts (Direct); Common Stock — 31,596 shares (Direct); Common Stock — 5,423 shares (Indirect, 2024 GRAT); Common Stock — 10,780 shares (Indirect, 2025 GRAT); Common Stock — 20,000 shares (Indirect, 2026 GRAT); Common Stock — 155,611 shares (Indirect, By Trust); Common Stock — 10,000 shares (Indirect, By Trust Held By Spouse)

Footnotes (1)

1. F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.

Key Figures

Shares sold: 33,561 shares of Common Stock Sale price: $300.00 per share Options exercised at $194.12: 21,132 stock options +5 more

8 metrics

Shares sold 33,561 shares of Common Stock Sale on August 25, 2026 at $300.00 per share

Sale price $300.00 per share Price for 33,561 CRL shares sold on August 25, 2026

Options exercised at $194.12 21,132 stock options Options to buy CRL common stock exercised on August 25, 2026

Options exercised at $208.44 12,429 stock options Options to buy CRL common stock exercised on August 25, 2026

Indirect holdings – 2024 GRAT 5,423 shares of Common Stock Indirect ownership through 2024 GRAT after transactions

Indirect holdings – 2025 GRAT 10,780 shares of Common Stock Indirect ownership through 2025 GRAT after transactions

Indirect holdings – Trust 155,611 shares of Common Stock Indirect ownership by trust after transactions

Indirect holdings – Spouse’s trust 10,000 shares of Common Stock Indirect ownership by trust held by spouse after transactions

Key Terms

Rule 10b5-1 Trading Plan, Stock Options (Right to Buy, Grantor Retained Annuity Trust, transaction code S

4 terms

Rule 10b5-1 Trading Plan regulatory

"This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy financial

"security_title": "Stock Options (Right to Buy)"

Grantor Retained Annuity Trust financial

"nature_of_ownership": "2024 GRAT"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

transaction code S regulatory

"transaction_code": "S","transaction_type": "non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRL director James C. Foster report on this Form 4?

He reported exercising stock options for 33,561 shares of CHARLES RIVER LABORATORIES common stock and selling 33,561 shares on August 25, 2026, along with updated indirect holdings in various trusts and Grantor Retained Annuity Trusts.

How many CRL shares did James C. Foster sell and at what price?

He sold 33,561 shares of CHARLES RIVER LABORATORIES (CRL) common stock at a price of $300.00 per share on August 25, 2026, in a sale reported with transaction code S for open market or private transactions.

What stock options did James C. Foster exercise in this CRL filing?

He exercised stock options on 21,132 shares with an exercise price of $194.12 per share and on 12,429 shares with an exercise price of $208.44 per share, receiving an equal number of CRL common shares on August 25, 2026.

Was the CRL share sale by James C. Foster under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026, and the Form 4’s Rule 10b5-1 checkbox is marked as affirmative.

What indirect CRL share holdings does James C. Foster report?

He reports indirect ownership of 5,423 shares via a 2024 GRAT, 10,780 via a 2025 GRAT, 20,000 via a 2026 GRAT, 155,611 shares held by a trust, and 10,000 shares held by a trust of his spouse.

Does this CRL Form 4 show net buying or selling activity?

It shows net selling activity. The transaction summary reports 33,561 shares exercised from options and an equal 33,561 shares sold, resulting in a net-sell share count of 33,561 for the reported buy/sell activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:23 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FOSTER JAMES C

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2026		M		21,132	A	$194.12	52,728	D
Common Stock	08/25/2026		M		12,429	A	$208.44	65,157	D
Common Stock	08/25/2026		S		33,561(1)	D	$300	31,596	D
Common Stock								5,423	I	2024 GRAT
Common Stock								10,780	I	2025 GRAT
Common Stock								20,000	I	2026 GRAT
Common Stock								155,611	I	By Trust
Common Stock								10,000	I	By Trust Held By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$194.12	08/25/2026		M			21,132	05/26/2024	05/26/2033	Common Stock	21,132	$0	7,044	D
Stock Options (Right to Buy)	$208.44	08/25/2026		M			12,429	05/31/2025	05/31/2034	Common Stock	12,429	$0	12,429	D

Explanation of Responses:

1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.

	/s/ James C. Foster	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)